Threshold Pharmaceuticals (MTEM) Receiving Somewhat Favorable Media Coverage, Study Shows

Media coverage about Threshold Pharmaceuticals (NASDAQ:MTEM) has trended somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies positive and negative press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Threshold Pharmaceuticals earned a daily sentiment score of 0.06 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 45.7685784072015 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

These are some of the headlines that may have impacted Accern Sentiment Analysis’s analysis:

Shares of Threshold Pharmaceuticals (MTEM) traded up $0.49 on Friday, reaching $7.55. 56,540 shares of the company were exchanged, compared to its average volume of 81,200. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.16 and a quick ratio of 6.16. Threshold Pharmaceuticals has a 12-month low of $3.85 and a 12-month high of $11.88.

A number of equities analysts have issued reports on MTEM shares. Zacks Investment Research cut shares of Threshold Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, September 14th. ValuEngine downgraded shares of Threshold Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, December 1st.

TRADEMARK VIOLATION NOTICE: “Threshold Pharmaceuticals (MTEM) Receiving Somewhat Favorable Media Coverage, Study Shows” was originally reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this news story on another website, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this news story can be read at https://stocknewstimes.com/2017/12/09/threshold-pharmaceuticals-mtem-receiving-somewhat-favorable-media-coverage-study-shows.html.

Threshold Pharmaceuticals Company Profile

Molecular Templates, Inc, formerly Threshold Pharmaceuticals, Inc, is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of therapeutic and diagnostic agents that selectively target tumor cells for the treatment of patients living with cancer. It is developing two therapeutic product candidates based on hypoxia-activated prodrug technology: evofosfamide and tarloxotinib.

Insider Buying and Selling by Quarter for Threshold Pharmaceuticals (NASDAQ:MTEM)

Receive News & Ratings for Threshold Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Threshold Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply